Get the Stockscreener App
0.00
100.00%
-9.71
Fibrogen Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$9.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$39.28M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
0.00
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$12.60
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.00 | 39.28M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Breakouts: Can FibroGen Inc be the next market leaderJuly 2025 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Returns Recap: What is the target price for FibroGen Inc stockTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio Announces Positive Data from the - GlobeNewswire
Earnings Risk: Is FibroGen Inc stock a value trapWeekly Stock Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
FibroGen (FGEN) Delisted: What’s Really Left for Shareholders? - AD HOC NEWS
Analyst Upgrade: Why is FibroGen Inc stock going up2025 Performance Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trading Recap: Is FibroGen Inc stock a value trap2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Sentiment Recap: Is FibroGen Inc stock heavily shorted2025 Historical Comparison & Weekly Watchlist of Top Performers - baoquankhu1.vn
Support Test: Will FibroGen Inc. benefit from rising consumer demandPortfolio Gains Summary & High Accuracy Buy Signal Tips - mfd.ru
Can FibroGen Inc. sustain its profitabilityEarnings Trend Report & Reliable Price Breakout Alerts - mfd.ru
Aug Volume: Will Global Indemnity Group LLC Preferred Security benefit from geopolitical trendsVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is FibroGen Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - mfd.ru
Jobs Data: Is FibroGen Inc stock a buy or sellEarnings Summary Report & Accurate Trade Setup Notifications - baoquankhu1.vn
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Movers: Will FibroGen Inc benefit from AI trends2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sentiment Review: Will FibroGen Inc benefit from AI trendsWeekly Market Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Quarterly Risk: Will FibroGen Inc benefit from AI trends2025 Retail Activity & Smart Allocation Stock Tips - baoquankhu1.vn
Price Action: Can FibroGen Inc be the next market leader2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
Aug Technicals: Will FibroGen Inc stock benefit from M AWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
Jobs Data: Will FibroGen Inc. stock outperform international peers2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Sentiment Review: Will FibroGen Inc benefit from government policyMarket Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Sentiment: Is FibroGen Inc. stock heavily shorted2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
RSI Check: Why FibroGen Inc stock remains on buy listsShort Setup & Reliable Intraday Trade Alerts - Bộ Nội Vụ
How FibroGen Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Risk Managed Investment Signals - Улправда
KYNB: Kyntra Bio IncFull Company Report - Zacks Investment Research
Trend Recap: Why FibroGen Inc. stock is a must watch in 2025Trade Signal Summary & Technical Confirmation Trade Alerts - ulpravda.ru
Why FibroGen Inc. stock is a must watch in 2025Market Growth Report & Fast Exit and Entry Trade Guides - Улправда
Aug Chart Watch: Is FibroGen Inc. stock undervalued vs historical averagesJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - Улправда
Published on: 2026-01-09 00:07:25 - Улправда
Is FibroGen Inc. stock a buy before product launches2025 Trading Recap & AI Based Trade Execution Alerts - Улправда
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - MarketScreener
FibroGen (FGEN) Faces Option Delistings as of January 8th - GuruFocus
One new option listing and one option delisting on January 8th - TipRanks
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB By Investing.com - Investing.com Nigeria
FibroGen nabs ex-Lilly Conterno as CEO - The Pharma Letter
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com South Africa
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen rebrands to Kyntra Bio - marketscreener.com
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):